AHSG (alpha-2-Heremans-Schmid glycoprotein), also known as fetuin-A, is a multifunctional hepatically-derived plasma protein with diverse physiological roles. Structurally, it is a 55-59 kDa phosphorylated glycoprotein that binds to tandem fibronectin type 3 domains on the insulin receptor β-subunit 1, thereby inhibiting insulin receptor tyrosine kinase activity and contributing to insulin resistance 1. AHSG also functions as a negative acute-phase reactant and physiological inhibitor of ectopic biomineralization, regulating bone remodeling and calcium metabolism while preventing vascular calcification 2. The protein promotes endocytosis and possesses opsonic properties enhancing phagocytosis. Genetically, AHSG polymorphisms significantly influence serum fetuin-A levels and associate with multiple disease states. In autoimmune disease, genetically-determined circulating AHSG levels show protective effects against multiple sclerosis (OR: 0.88 per standard deviation increase), identifying it as a potential drug target 3. Conversely, elevated AHSG expression promotes lung adenocarcinoma progression through enhanced proliferation, migration, and invasion via epithelial-mesenchymal transition, serving as an independent prognostic factor for poor overall survival 4. In metabolic disease, AHSG mediates associations between genetic variation and bone mineral density through fetuin-A and BMI pathways 5, while dysregulated AHSG contributes to type 2 diabetes and metabolic syndrome 6. AHSG polymorphisms also associate with endometriosis risk 7 and vascular calcification in dialysis patients 8.